LLY

969.62

-3.14%↓

JNJ

236.78

-3.59%↓

ABBV

228.95

-2.31%↓

NVS

159.49

-2.93%↓

AZN

196.22

-2.82%↓

LLY

969.62

-3.14%↓

JNJ

236.78

-3.59%↓

ABBV

228.95

-2.31%↓

NVS

159.49

-2.93%↓

AZN

196.22

-2.82%↓

LLY

969.62

-3.14%↓

JNJ

236.78

-3.59%↓

ABBV

228.95

-2.31%↓

NVS

159.49

-2.93%↓

AZN

196.22

-2.82%↓

LLY

969.62

-3.14%↓

JNJ

236.78

-3.59%↓

ABBV

228.95

-2.31%↓

NVS

159.49

-2.93%↓

AZN

196.22

-2.82%↓

LLY

969.62

-3.14%↓

JNJ

236.78

-3.59%↓

ABBV

228.95

-2.31%↓

NVS

159.49

-2.93%↓

AZN

196.22

-2.82%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.35 -4.93

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.35

Max

1.47

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+179.56% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-1.2M 173M
Eelmine avamishind	6.28
Eelmine sulgemishind	1.35

Uudiste sentiment

By Acuity

20%

80%

37 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. märts 2026, 23:39 UTC

Kuumad aktsiad

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4. märts 2026, 23:20 UTC

Tulu

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4. märts 2026, 21:43 UTC

Tulu

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4. märts 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

4. märts 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4. märts 2026, 23:24 UTC

Market Talk

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4. märts 2026, 22:30 UTC

Tulu

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4. märts 2026, 22:30 UTC

Tulu

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4. märts 2026, 22:30 UTC

Tulu

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4. märts 2026, 22:13 UTC

Tulu

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4. märts 2026, 22:13 UTC

Tulu

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4. märts 2026, 22:13 UTC

Tulu

Vermilion Energy 4Q EPS C$2.86 >VET

4. märts 2026, 22:04 UTC

Market Talk

RBA Slipping Behind The Curve On Rates -- Market Talk

4. märts 2026, 21:53 UTC

Tulu

Lithium Americas 4Q Rev $66.8M >LAC

4. märts 2026, 21:53 UTC

Tulu

Lithium Americas 4Q Loss/Shr 52c >LAC

4. märts 2026, 21:52 UTC

Tulu

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4. märts 2026, 21:50 UTC

Tulu

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4. märts 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. märts 2026, 21:48 UTC

Tulu

Webull 4Q Rev $165.2M >BULL

4. märts 2026, 21:48 UTC

Tulu

Webull 4Q EPS 1c >BULL

4. märts 2026, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. märts 2026, 21:45 UTC

Market Talk

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4. märts 2026, 21:40 UTC

Tulu

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4. märts 2026, 21:36 UTC

Uudisväärsed sündmused

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4. märts 2026, 21:27 UTC

Tulu

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4. märts 2026, 21:17 UTC

Market Talk

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4. märts 2026, 21:16 UTC

Tulu

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4. märts 2026, 21:15 UTC

Tulu

Broadcom 1Q EPS $1.50 >AVGO

4. märts 2026, 21:15 UTC

Tulu

Broadcom 1Q Net $7.35B >AVGO

4. märts 2026, 21:15 UTC

Tulu

Broadcom 1Q Rev $19.31B >AVGO

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

179.56% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 179.56%

Kõrge 7 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

37 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.